INTRODUCTION:

The development of drugs to treat uncommon diseases presents significant challenges since there are fewer patients and we don't know how the diseases work. It is very difficult to develop treatments for rare diseases because they face additional regulatory hurdles, high development costs, and limited commercial returns, which make their development more difficult. Recent advancements in drug development and regulatory incentives have made it possible to discover treatments for uncommon diseases. Developing drugs for uncommon diseases poses a number of challenges and opportunities, as described in this article¹. In the European Union, less than 5,000 people suffer from uncommon diseases. Since these diseases often present in complex, heterogeneous clinical presentations, they are associated with a lot of morbidity and mortality.

Common and uncommon diseases: prevalence and impact

There are approximately 300 to 400million people worldwide who suffer from uncommon diseases, which collectively affect a significant part of the global population and are a major cause of death for them². The quality of life and morbidity of a number of uncommon diseases can have serious repercussions for patients and their families as well as their quality of life³. Rare diseases place significant burdens on healthcare systems due to their high costs and limited treatment options⁴.

Uncommon disease drug development challenges

There are many barriers to drug development for uncommon diseases, such as a lack of understanding of the disease, limited populations of patients, and regulatory hurdles⁵. Due to the small number of patients and the lack of available patient data, there is a shortage of patients and limited availability of patient data⁶. A lack of understanding of uncommon diseases can also delay the approval of new therapies by identifying appropriate targets for drug development⁷. A lack of commercial returns and high development costs can discourage investment in rare disease drug development.

MATERIALS AND METHODS:

a) Incidence of rare diseases and drug development:

The development of drugs for uncommon diseases has been characterized by significant advances despite many challenges. Therapeutics for rare diseases have been developed thanks to regulation, such as the designation of orphan drugs and accelerated approval mechanisms⁸. Advances in genomics and personalized medicine have also enabled targeted therapies for uncommon diseases⁹. Through repurposing existing drugs and developing innovative trial designs, drug development for uncommon diseases has also been improved¹⁰^,¹¹.

An incentive-based approach to drug development for rare diseases:

Tax incentives, accelerated approval pathways, and orphan drug designations are available to promote the development of uncommon disease drugs¹²^,¹³.

Identifying and approving orphan drugs:

In order for orphan drugs to be developed, they are granted regulatory incentives and faster approval pathways so that they are able to be developed for rare diseases¹⁴. The development of these drugs is thereby influenced by regulatory incentives¹⁵^,¹⁶.

Rare disease drug development trends:

As precision medicine advances, there is a growing emphasis on repurposing existing drugs for rare diseases¹⁷. This has allowed the development of more targeted and cost-effective treatments for rare diseases thanks to some advancements in precision medicine.

A successful example of a drug developed for an uncommon disease:

Rare diseases will be treated with gene therapies, enzyme replacement therapies, and other therapies to address genetic disorders such as spinal muscular atrophy and inherited retinal diseases¹⁸. These therapies have been very beneficial to patients with these rare diseases¹⁹.

b) The development of new drugs for uncommon diseases:

Innovations in drug development for uncommon diseases include using biomarkers, repurposing existing drugs, and engaging patients. Drug development can be accelerated through the use of biomarkers that identify patients who would benefit from treatment. The repurposing of existing drugs for rare diseases can speed up drug development and save resources. It is possible to design therapies that are patient-centered by involving patients in the development process. Innovative clinical trial designs can also improve drug development efficiency for uncommon diseases through platform trials or basket trials.

Precision medicine and medicine based on individual needs:

Through personalized medicine and precision therapy, genetic and biomarker information can be used to develop treatment plans tailored to the individual patient.

Therapies involving gene editing and gene therapy:

By rectifying the underlying genetic defect causing an uncommon disease, gene therapy and gene editing can introduce healthy genes or repair defective genes.

Combination therapies and repurposing of drugs:

Innovative approaches to treating uncommon diseases can be achieved through the repurposing of existing drugs or the combination of multiple therapies.

Involvement of patients in drug development and advocacy:

The design, recruitment, and regulatory decision-making processes of drug development include advocacy and engagement of patients. The perspective of the patient will improve drug development.

c) Prospects for developing drugs to treat uncommon diseases:

There is no doubt that the future of drug development for uncommon diseases will be influenced by precision medicine, personalized treatment, gene therapy, gene editing technologies, and patient advocacy groups' and patients' involvement in drug development. Precision medicine, personalized treatment, gene therapies, gene editing technologies, and innovative trial designs will continue to shape drug development. Through their use of real-world data and artificial intelligence, artificial intelligence and machine learning offer new opportunities for developing therapies for uncommon diseases. Collaboration among stakeholders, including patient advocacy groups, industry, and regulatory agencies, will also be essential to improving patient outcomes for uncommon diseases.

Technological advances in genomics and molecular biology:

Genetic mutations and biomarkers associated with uncommon diseases have been identified by advances in genomics and molecular technologies. The development of precision therapies for uncommon diseases has been facilitated by CRISPR gene editing and next-generation sequencing. By identifying patient subgroups that will benefit the most from a therapy, these technologies also allow for more efficient and targeted drug development.

Patients are at the centre of drug development and regulation:

The importance of conducting clinical trials and getting sufficient patient data in a collaborative manner has become increasingly important as we progress towards developing drugs for uncommon diseases, since these diseases affect a relatively small number of patients. In order to address these challenges, collaborative research and data sharing initiatives, like the Global Uncommon Diseases Registry and Data Repository, facilitate the sharing of patient data, promote collaboration between researchers and industry, and encourage the development of more effective therapies for uncommon diseases. It is anticipated that this will result in an increase in the efficiency of drug development, which will lead to improved outcomes for patients suffering from diseases that are uncommon.

Regulations and drug development cantered on patients:

During drug development, patient perspectives are prioritized through identifying patient-relevant endpoints, including patients in trial design, recruiting patients, and considering their perspectives during the regulatory process.

d) Drug development for uncommon diseases: challenges and opportunities:

A number of new challenges are emerging as the cost of drug development for uncommon diseases rises, the design of clinical trials needs to be more efficient, and patients with rare diseases have limited access to therapies, all of which translate into the development of drug therapies. It is essential that innovative technologies are used to address these challenges and improve patient outcomes, as well as the participation of patient advocacy groups in drug development in order to address these challenges.

DISCUSSION:

Pharmaceutical companies and researchers face significant challenges when developing treatments for uncommon diseases, as discussed in the section on drug development for uncommon diseases. These challenges include a lack of understanding of the disease, a limited number of patients, and regulatory obstacles. The advancement of genomics and molecular technology has led to an increase in drug development for uncommon diseases. Moreover, involving patients in the development of therapies may have a positive effect on patient outcomes by improving therapeutic effectiveness as a result of meeting their needs. By repurposing existing drugs for new indications and using existing drugs in combination, innovative trial designs can be used to develop drugs for uncommon diseases more efficiently, whereas combination therapies can provide patients with alternative treatment options by combining existing drugs. Collaboration between patient advocacy groups, industry, and regulatory agencies is needed to address the challenges in uncommon disease drug development and to improve patient outcomes.

CONCLUSION:

Regulatory incentives and advances in drug development have led to an increase in treatments for uncommon diseases due to challenges associated with the development of drugs for uncommon diseases, such as limited patient populations and regulatory hurdles. It is expected that gene therapies and innovative trial designs will play a major role in the development of uncommon disease drugs in the future, as well as patients and patient advocacy groups becoming more involved in the development of drugs, as well as developing drugs in innovative ways, such as with precision medicine.

Implications for uncommon disease patients, healthcare providers, and drug developers:

Patients, healthcare providers, and pharmaceutical companies all benefit from the development of medicines for uncommon diseases. By developing new and effective treatments for uncommon diseases, it can improve patients' quality of life and reduce their morbidity and mortality. Improved healthcare providers, better treatment options, and a better understanding of uncommon diseases can result in better patient outcomes. Developing drugs to address unmet medical needs and treat uncommon diseases can provide pharmaceutical companies with significant commercial returns. A limited patient population, high costs, and regulatory hurdles are some challenges in the development of drugs for uncommon diseases.

Directions for future research and policy development:

For the development and approval of drugs for uncommon diseases, new approaches, such as gene therapy and gene editing, are required, as well as improved patient engagement and collaboration between stakeholders, such as patient advocacy groups, industry, and regulatory agencies. In terms of policy development, access to treatment and costs of drugs should be addressed in order to ensure that affordable and effective therapies are available to patients with uncommon diseases.

CONFLICT OF INTEREST:

The authors have no conflicts of interest regarding this investigation.

REFERENCES:

1. Epps C, Bax R, Croker A, et al. Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases. Ther Innov Regul Sci. 2022; 56(6): 964-975. doi:10.1007/s43441-022-00409-w

2. Miller KL, Fermaglich LJ, Maynard J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021; 16(1). doi:10.1186/s13023-021-01901-6

3. Pontes C, Fontanet JM, Vives R, et al. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: Methodological uncertainties. Orphanet J Rare Dis. 2018; 13(1). doi:10.1186/s13023-018-0926-z

4. Casamento K, Laverty A, Wilsher M, et al. Assessing the feasibility of a web-based registry for multiple orphan lung diseases: The Australasian Registry Network for Orphan Lung Disease (ARNOLD) experience. Orphanet J Rare Dis. 2016; 11(1). doi:10.1186/s13023-016-0389-z

5. Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Intern Med. 2019; 179(7): 906-913. doi:10.1001/jamainternmed.2019.0462

6. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable Rare Dis Res. 2012; 1(1): 3-9. doi:10.5582/irdr.2012.v1.1.3

7. Aartsma-Rus A, Dooms M, Le Cam Y. Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group). Front Pharmacol. 2021; 12. doi:10.3389/fphar.2021.744532

8. Austin CP, Cutillo CM, Lau LPL, et al. Future of Rare Diseases Research 2017–2027: An IRDiRC Perspective. Clin Transl Sci. 2018;11(1):21-27. doi:10.1111/cts.12500

9. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis. 2008; 3(1). doi:10.1186/1750-1172-3-33

10. Narala SR, Saraswathi K. Application of Oxidants to the Spectrophotome tric Determination of Cephalosporins (Cefditoren Pivoxil and Cefdinir) In Formulations. Tablet. 2011; 1(200): 187-199.

11. Patil KB, Patil NB, Patil AA. Medicinal Plants for cure Common Diseases in Shirpur (Maharashtra, India). Asian J Res Pharm Sci. 2019;9(4):273. doi:10.5958/2231-5659.2019.00043.2

12. Hapse SA, Tarkase KN, Jadhav AS, Dongare US. Study and Evaluation of Dry Powder Inhaler- A Review. 2011;3(3):87-92.

13. Banerjee J, Padmalatha H, Ramesh K, Chanda R. Formulation and Evaluation of Fast Dissolving Tablets of Cefdinir by Employing Solid Dispersion. 2018; 10(03): 169-174. doi:10.5958/0975-4377.2018.00026.5

14. Article R. New Technologies in Particulate Engineering for Pulmonary Delivery of Macromolecule. 2011; 4(February): 167-174.

15. Kumar RS, Priya BL. A Mutated Transmembrane Conductance Regulator Protein Targeted for Cystic Fibrosis – An In silico Analysis. 2017; 10(November):3697-3700. doi:10.5958/0974-360X.2017.00670.9

16. Ramanjaneyulu K V, K VR, Rao MP. Stability indicating LC Method Development and Validation for the Simultaneous analysis of Cystic Fibrosis Drugs - Ivacaftor and Tezacaftor in Pharmaceutical Formulations. 2020;13(May):2076-2080. doi:10.5958/0974-360X.2020.00373.X

17. Dhekale KD, Kamble RN. Development of cefdinir loaded Functionalized carbon Nanotubes dry powder Inhaler for the Treatment of cystic Fibrosis. 2021;14(July):3839-3845. doi:10.52711/0974-360X.2021.00666

18. Dutta D, Chakraborty P. Orphan Drugs - Its pros and cons. 2009;1(2):59-66.

19. Arjun S, Venkatesh MP, Balamuralidhara V, Kumar TMP. Expedited programs for Drug Development and Approval in USA. 2020; 13(March): 1409-1414. doi:10.5958/0974-360X.2020.00258.9

Received on 01.05.2023 Modified on 14.09.2023

Research J. Pharm. and Tech 2024; 17(5):2405-2408.

DOI: 10.52711/0974-360X.2024.00376